Release Date: Monday, November 1, 2021
       Expiration Date: Tuesday, November 1, 2022


Overactive bladder (OAB) is a chronic, debilitating condition that impacts approximately 16% of the population in the United States. OAB is more prevalent in older adults, with one estimate of 40.4% in elderly men and 46.9% in elderly women. Though OAB is a common problem, relatively few individuals with symptoms of OAB seek medical care and even fewer receive care. For this reason, OAB is often termed the “hidden condition” as many who suffer from the condition consider OAB a normal part of aging and fail to report it to their physician. Left untreated, OAB can significantly impact a patient’s quality of life, including physical, psychological, social, occupational, and sexual aspects. 

Clinicians in the primary care setting are well positioned to improve the outcomes of patients with OAB symptoms by early detection and effective utilization of current management approaches. PCPs must communicate with patients initially about recognizing OAB symptoms, and then by developing realistic patient-specific treatment goals that meet patient expectations. Through routine evaluation of treatment effectiveness and tolerability while making necessary adjustments, PCPs can make a significant impact in improving the overall well-being of patients with OAB.


This continuing education activity meets the needs of primary care providers including internists, family physicians, osteopathic physicians, physician assistants, and nurse practitioners. This program targets PCPs who are involved in the evaluation, screening, and diagnosis of OAB as well as those who participate in the management of these patients.


At the conclusion of the educational activity, the learner should be able to:

  • Proactively evaluate and screen at-risk individuals for overactive bladder (OAB)
  • Utilize communication strategies aimed to evaluate the impact of OAB on quality of life and educate patients on appropriate treatment options and expectations
  • Select patients with OAB who would benefit from combination therapy to maximize efficacy and tolerability


This online presentation builds competence, confidence, and skills in the understanding of how to utilize patient-provider communication and management approaches to improve patient health outcomes while reducing disease burden. 

The faculty presentation emphasizes the importance of adequate communication with patients with OAB at various stages of patient care. The faculty discusses the need for communication and patient education at each stage, including starting a dialog about OAB symptoms, understanding patient expectations with treatment, and setting realistic patient-centered treatment goals. Best practices in OAB management are presented at the various stages of disease and emphasize a treat-to-target approach that involves regular follow-up to evaluate patient outcomes and tolerability followed by treatment adjustment when needed. The advantages of combination therapy are discussed, and faculty reviews which patient types would best benefit from this approach. The emphasis is placed on the importance of utilizing evidence-based approaches to care and individualizing treatment options when managing OAB based on patient response to therapy. 

The presentation covers the following topics: 

  • Identifying the at-risk population 
  • Initiating the conversation about OAB 
  • Making the differential diagnosis 
  • AUA/SUFU guideline recommendations 
  • Implementing a treat-to-target approach 
  • Evaluating patient outcomes and expectations 
  • Managing adverse effects 
  • Selecting patients for combination therapy  


Patrick J. Shenot, MD
Professor of Urology
Residency Program Director
Deputy Chair, Department of Urology
Thomas Jefferson University
Philadelphia, PA 




This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME. 


Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CME information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Certificate of Credit will be emailed to you within 4 weeks.

Disclosure of Financial Relationships with Ineligible Companies
Center for Independent Healthcare Education and Vemco MedEd fully comply with the Standards for Integrity and Independence in Accredited Continuing Education in development of CME/CPE activities. We require the full disclosure of financial relationships with ineligible companies from all individuals in a position to influence the content of a certified activity, in any amount occurring within the past 24 months. All relevant financial relationship is identified by the provider and mitigated to prevent inserting commercial bias into content. All identified relevant financial relationships are disclosed to the learners prior to the activity. The faculty is further required to disclose discussion of off-label uses in their presentations.



Patrick Shenot, MD has relevant financial relationships with ineligible companies to disclose:
   Consultant: Merck & Co., Inc.

All relevant financial relationships have been mitigated. Dr. Shenot does not intend to discuss the off-label use of a product 

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation. 


There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2021 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.

By clicking below, I acknowledge that I have read the entire CME information.